{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:46:01Z","timestamp":1785527161249,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"US Public Health Service","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The role of axillary surgery in patients with de novo metastatic breast cancer (dnMBC) undergoing primary site surgery is unclear. We evaluated patterns of axillary management and associations with overall survival (OS) in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the National Cancer Database (2012-2020) to identify patients with dnMBC. Patients were grouped by receipt of breast surgery and axillary surgery (none, sentinel lymph node biopsy [SLNB] or axillary lymph node dissection [ALND]). Multivariable Cox proportional hazards models assessed factors associated with axillary surgery and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 39,946 eligible patients, 7,808 (19.5%) underwent surgery of the primary site, of whom 79.8% underwent axillary surgery (79.5% ALND, 20.4% SLNB). Compared with no axillary surgery, those who underwent axillary surgery had more favorable clinicodemographic characteristics (younger, fewer comorbidities, lower T stage, bone-only metastases). In patients with clinically node-negative disease, 41.6% had pathologically negative nodes, with higher rates among those with HR+\/HER- disease and those who did not have systemic therapy prior to surgery. On multivariable analysis, axillary surgery was independently associated with improved OS (HR 0.70; 95% CI 0.63\u20130.78; p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with dnMBC undergoing primary site surgery, axillary surgery was associated with improved survival in this retrospective analysis, though the effect is likely influenced by selection bias. Until prospective data define which subgroups may benefit, axillary surgery should be considered selectively, with SLNB preferred over ALND for patients without palpable adenopathy to minimize morbidity. Multidisciplinary evaluation remains essential to tailor surgical decisions that balance survival, function, and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07998-2","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:50:24Z","timestamp":1782129024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of axillary surgery on survival in de novo metastatic breast cancer with primary tumor resection"],"prefix":"10.1007","volume":"217","author":[{"given":"Mahtab","family":"Vasigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison A.","family":"Aggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"7998_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/CAAC.21820","volume":"74","author":"RL Siegel Mph","year":"2024","unstructured":"Siegel Mph RL, Giaquinto AN, Ahmedin, | et al (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/CAAC.21820","journal-title":"CA Cancer J Clin"},{"key":"7998_CR2","doi-asserted-by":"publisher","unstructured":"Tosello G, Torloni MR, Mota BS et al (2018) Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 3. https:\/\/doi.org\/10.1002\/14651858.CD011276.PUB2","DOI":"10.1002\/14651858.CD011276.PUB2"},{"key":"7998_CR3","doi-asserted-by":"publisher","unstructured":"Lord SJ, Bahlmann K, O\u2019Connell DL et al (2022) De novo and recurrent metastatic breast cancer \u2013 a systematic review of population-level changes in survival since 1995. EClinical Medicine 44. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101282","DOI":"10.1016\/j.eclinm.2022.101282"},{"key":"7998_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.AMJSURG.2021.07.018","volume":"223","author":"CE Marks","year":"2022","unstructured":"Marks CE, Thomas SM, Fayanju OM et al (2022) Metastatic breast cancer: Who benefits from surgery? Am J Surg 223:81\u201393. https:\/\/doi.org\/10.1016\/J.AMJSURG.2021.07.018","journal-title":"Am J Surg"},{"key":"7998_CR5","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1245\/S10434-012-2844-Y","volume":"20","author":"JE Lang","year":"2013","unstructured":"Lang JE, Tereffe W, Mitchell MP et al (2013) Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol 20:1893\u20131899. https:\/\/doi.org\/10.1245\/S10434-012-2844-Y","journal-title":"Ann Surg Oncol"},{"key":"7998_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/JAMASURG.2015.4539","volume":"151","author":"A Thomas","year":"2016","unstructured":"Thomas A, Khan SA, Chrischilles EA, Schroeder MC (2016) Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988\u20132011. JAMA Surg 151:424\u2013431. https:\/\/doi.org\/10.1001\/JAMASURG.2015.4539","journal-title":"JAMA Surg"},{"key":"7998_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.breast.2011.06.005","volume":"20","author":"JA P\u00e9rez-Fidalgo","year":"2011","unstructured":"P\u00e9rez-Fidalgo JA, Pimentel P, Caballero A et al (2011) Removal of primary tumor improves survival in metastatic breast cancer. Does timing Surg influence outcomes? Breast 20:548\u2013554. https:\/\/doi.org\/10.1016\/j.breast.2011.06.005","journal-title":"Does timing Surg influence outcomes? Breast"},{"key":"7998_CR8","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/J.CLBC.2017.07.005","volume":"18","author":"W Chen","year":"2018","unstructured":"Chen W, Huang Y, Lewis GD et al (2018) Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study. Clin Breast Cancer 18:e97\u2013e105. https:\/\/doi.org\/10.1016\/J.CLBC.2017.07.005","journal-title":"Clin Breast Cancer"},{"key":"7998_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1245\/S10434-010-1016-1","volume":"17","author":"BA Pockaj","year":"2010","unstructured":"Pockaj BA, Wasif N, Dueck AC et al (2010) Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol 17:2419\u20132426. https:\/\/doi.org\/10.1245\/S10434-010-1016-1","journal-title":"Ann Surg Oncol"},{"key":"7998_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2019.03.006","volume":"45","author":"X Li","year":"2019","unstructured":"Li X, Huang R, Ma L et al (2019) Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis. Breast 45:104\u2013112. https:\/\/doi.org\/10.1016\/j.breast.2019.03.006","journal-title":"Breast"},{"key":"7998_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.21.02006","volume":"40","author":"SA Khan","year":"2022","unstructured":"Khan SA, Zhao F, Goldstein LJ et al (2022) Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). J Clin Oncol 40:978\u2013987. https:\/\/doi.org\/10.1200\/JCO.21.02006","journal-title":"J Clin Oncol"},{"key":"7998_CR12","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/S10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S et al (2018) Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol 25:3141\u20133149. https:\/\/doi.org\/10.1245\/S10434-018-6494-6","journal-title":"Ann Surg Oncol"},{"key":"7998_CR13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol 16:1380\u20131388. https:\/\/doi.org\/10.1016\/S1470-2045(15)00135-7","journal-title":"Lancet Oncol"},{"key":"7998_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/SLA.0000000000002771","volume":"269","author":"F Fitzal","year":"2019","unstructured":"Fitzal F, Bjelic-Radisic V, Knauer M et al (2019) Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg 269:1163\u20131169. https:\/\/doi.org\/10.1097\/SLA.0000000000002771","journal-title":"Ann Surg"},{"key":"7998_CR15","doi-asserted-by":"publisher","unstructured":"Lisboa FCAP, Silva RB, de Andrade KRC et al (2020) Axillary surgical approach in metastatic breast cancer patients: a systematic review and meta-analysis. Ecancermedicalscience 14. https:\/\/doi.org\/10.3332\/ECANCER.2020.1117","DOI":"10.3332\/ECANCER.2020.1117"},{"key":"7998_CR16","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1097\/SLA.0000000000004767","volume":"277","author":"J Hotton","year":"2023","unstructured":"Hotton J, Lusque A, Leufflen L et al (2023) Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort. Ann Surg 277:E153\u2013E161. https:\/\/doi.org\/10.1097\/SLA.0000000000004767","journal-title":"Ann Surg"},{"key":"7998_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/J.JAMCOLLSURG.2021.08.686","volume":"233","author":"A Soran","year":"2021","unstructured":"Soran A, Ozmen V, Ozbas S et al (2021) Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. J Am Coll Surg 233:742\u2013751e5. https:\/\/doi.org\/10.1016\/J.JAMCOLLSURG.2021.08.686","journal-title":"J Am Coll Surg"},{"key":"7998_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.21037\/GS-24-130\/COIF)","volume":"13","author":"YL Wu","year":"2024","unstructured":"Wu YL, Hong YY, Zhan HL et al (2024) Axillary lymph node removal in de novo metastatic breast cancer. Gland Surg 13:1214\u20131228. https:\/\/doi.org\/10.21037\/GS-24-130\/COIF)","journal-title":"Gland Surg"},{"key":"7998_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/JAMA.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial. JAMA 305:569\u2013575. https:\/\/doi.org\/10.1001\/JAMA.2011.90","journal-title":"JAMA"},{"key":"7998_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u2009\u2013\u200901): A phase 3 randomised controlled trial. Lancet Oncol 14:297\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(13)70035-4","journal-title":"Lancet Oncol"},{"key":"7998_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/JNCI\/DJJ158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599\u2013609. https:\/\/doi.org\/10.1093\/JNCI\/DJJ158","journal-title":"J Natl Cancer Inst"},{"key":"7998_CR22","doi-asserted-by":"publisher","unstructured":"Fisher B, Montague E, Redmond C et al (1980) Findings from NSABP protocol no. B-04-comparison of radical mastectomy with alternative rreatments for primary breast cancer 1. Radiation Compliance and its Relation to Treatment Outcome. https:\/\/doi.org\/10.1002\/1097-0142(19800701)46:1","DOI":"10.1002\/1097-0142(19800701)46:1"},{"key":"7998_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1308\/003588403321661299","volume":"85","author":"GQ Della Rovere","year":"2003","unstructured":"Della Rovere GQ, Ahmad I, Singh P et al (2003) An audit of the incidence of arm lymphoedema after prophylactic level I\/II axillary dissection without division of the pectoralis minor muscle. Ann R Coll Surg Engl 85:158\u2013161. https:\/\/doi.org\/10.1308\/003588403321661299","journal-title":"Ann R Coll Surg Engl"},{"key":"7998_CR24","doi-asserted-by":"crossref","unstructured":"Warmuth MA, Bowen G, Prosnitz LR et al (1998) Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer 83(7):1362-8. https:\/\/www.sciepub.com\/reference\/306467. Accessed 20 Nov 2025","DOI":"10.1002\/(SICI)1097-0142(19981001)83:7<1362::AID-CNCR13>3.0.CO;2-2"},{"key":"7998_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.suronc.2006.11.003","volume":"15","author":"GH Sakorafas","year":"2006","unstructured":"Sakorafas GH, Peros G, Cataliotti L, Vlastos G (2006) Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 15:153\u2013165. https:\/\/doi.org\/10.1016\/j.suronc.2006.11.003","journal-title":"Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07998-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07998-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07998-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:29Z","timestamp":1785521369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07998-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7998"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07998-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Bleicher, Aggon, and Williams are consultants for Elucent Medical. All other authors have no disclosures.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}